Navigation Links
Cannabis Science Signs Lease for New 6,600 sq. ft. Corporate Headquarters and Laboratory Facility

COLORADO SPRINGS, Colo., Dec. 14, 2010 /PRNewswire/ -- Cannabis Science, Inc. (OTC Bulletin Board: CBIS) a pioneering U.S. biotech company developing pharmaceutical cannabis products, is pleased to announce it has signed a lease for a new corporate headquarters as its new base of operations in Denver, Colorado. The 6,600 sq. ft. core facility at 2422 S. Trenton Way, Unit H will be dedicated to housing executive offices, administrative personnel, as well as the Lab Division core of operations for its cannabis formulations testing and FDA initiatives.

"Needless to say we are very happy that with the support and patience of our investors we have achieved this milestone. This facility will be the Cannabis Science core and is an instrumental step in accomplishing our short and long-term goals of carrying out the basic and applied research needed to provide the best Cannabis Science products to patients. Uniquely, Cannabis Science will serve both the dispensary market, through licensing our technologies and analytical capabilities, and the pharmaceutical market, by working through the FDA approval process," stated Dr. Robert Melamede, CEO.

The company has executed a five-year lease on the facility in order to provide stable growth during our development phase. In our new corporate headquarters, the Company will facilitate customer communications while we mature our operations. Up till now, the Company has focused on developing out corporate structure and preliminary financial base. We now have the facility to centralize and expand our staff. As we expand our infrastructure, we will be more responsive to the overwhelming number of inquiries that we receive from patients, investors and the media.

The new laboratory facility will include analytical chemistry and genetic instrumentation, extraction equipment, as well as genetic and cell culture facilities. Our intent is to meet or exceed all federal, state, and local regulatory requirements particularly with respect to meeting FDA standards. Cannabis Science is currently working diligently to proceed down the FDA regulatory path. Our new facility will expedite this process.

Cannabis Science previously announced, on 8 July 2010, the execution of a lease on a 9,500 square foot facility in Denver that is now solely housing the grow operation of its licensed partner Rockbrook, Inc., in compliance with the current licensing requirements of the State of Colorado for a horticulture facility, infused products facility, and medical cannabis dispensary.

About Cannabis Science, Inc.Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development.  The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products.  In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking StatementsForward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs.  Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.Cannabis Science, Inc.

Cannabis Science, Inc.Dr. Robert J. Melamede

Mark J. FriedmanPresident & CEO

Investor  1-888-889-0888

1-877-431-CBIS (2247)

SOURCE Cannabis Science, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cannabis Science Announces a Proposed 10:1 Ratio Structured Dividend Payout for a New Class of Common Shares to Shareholders of Record as of November 30, 2010
2. CNBC, Discovery Channel and National Geographic to Cover Dr. Robert Melamede and Richard Cowan of Cannabis Science Whom are Speaking at The Marijuana Conference in New York City on Oct. 25 & 26
3. Cannabis Science Issues Guidance on Its Progress Toward FDA Investigative New Drug Applications For Clinical Trials and Proposed Dividend Payout for Current Shareholders to Receive a New Class of Common Stock
4. DC Patients Cooperative Urges Changes to the Proposed Medical Cannabis Marijuana Regulations
5. Medical Cannabis University™ Launches, Puts Thousands Back to Work to Help Veterans and the Chronically Ill
6. WuXi PharmaTech Presents 2010 Life Science and Chemistry Awards
7. Caliper Life Sciences to Acquire Cambridge Research & Instrumentation
8. Reportlinker Adds Gilead Sciences: PharmaVitae Profile
9. Sofie Biosciences Raises $2M to Support Development of Diagnostic Imaging Agents and Devices
10. Oxford Finance Corporation Hires Debbie Baker to Support Life Science Business Development in Western North America
11. LABS Inc. Adds Life Sciences Industry Veteran Kevin M. Smith to Board of Directors
Post Your Comments:
(Date:11/27/2015)... 2015  Lannett Company, Inc. (NYSE: LCI ... acquisition of Kremers Urban Pharmaceuticals Inc. (KU), the ... company UCB S.A. (Euronext: UCB). ... KU from UCB for total consideration of approximately ... customary working capital adjustment, a deduction of certain ...
(Date:11/27/2015)... 26, 2015 ... the "2016 Global Tumor Marker Testing ... and Sales Segment Forecasts, Innovative Technologies, Instrumentation ... to their offering. --> ... "2016 Global Tumor Marker Testing Market: ...
(Date:11/26/2015)... Un nuevo enfoque combina la ... cáncer avanzado.   --> Un nuevo ... Bremachlorin para el cáncer avanzado.   --> ... la terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... --> Clinical Cancer Research . --> ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... 2015 , ... An inventor, from Hopkinsville, Ky., thought there ... home, so he invented the patent-pending ELECTRONIC M.D. , The ELECTRONIC M.D. provides ... so, it could help to prevent potential overdose situations. As a result, it ...
(Date:11/27/2015)... Aliso Viejo, CA (PRWEB) , ... November 27, 2015 , ... ... exclusively for use in Final Cut Pro X. With ProSidebar: Fasion, video editors ... banners, or use ProSidebar as a minimalist title opener. Utilize presets featuring self-animating ...
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television ... an interesting show that delves into an array of issues that are presently affecting ... benefit from open dialogue, this show is changing the subjects consumers focus on, one ...
(Date:11/27/2015)... ... November 27, 2015 , ... The men and ... nonprofit healthcare organizations in the country. They have overseen financial turnarounds, shown commitment ... advance the healthcare industry as a whole through their advocacy and professional efforts. ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity Point ... come together on Thanksgiving Day to share the things that they are most ... Serenity Point YouTube channel, patients displayed what they wrote on index cards, describing ...
Breaking Medicine News(10 mins):